Summary The diagnosis and monitoring of leukaemia and lymphoma requires the effective integration of a wide range of diagnostic techniques and expertise. The need to develop this type of service that crosses traditional boundaries of laboratory specialities is being recommended in national guidance. The Haematological Malignancy Diagnostic Service based within the Leeds Teaching Hospitals NHS Trust was established in 1993 to provide specialist laboratory services for the diagnosis of haematological malignancy for Yorkshire and Humberside in the UK. The department uses a wide range of methodologies including morphology, immunocytochemistry, flow cytometry and molecular genetics [fluorescent in situ hybridization (FISH) and polymerase chain reaction (PCR)] in a systematic and co-ordinated way. We describe how the department was established, its current working practices and highlight the advantages of an integrated laboratory for diagnosis of tumours of the haematopoietic system.
Introduction
The National Institute for Clinical Excellence (NICE) has recently published service guidelines for the National Health Service (NHS) in England and Wales for improving outcomes in haemato-oncology (National Institute for Clinical Excellence, 2003) . These guidelines encompass the standards required for diagnosis, treatment and management of patients with tumours of the haematopoietic system. This guidance was produced in response to evidence that suggested an unacceptable error rate in diagnosis. Within this document emphasis is given to the development of centralized specialist laboratory services that use a combined approach to establish accurate and precise diagnoses of tumours of the haematopoietic system. It is envisaged that these specialist laboratories will be based on a number of modalities and expertise that are currently found within several of the more traditional pathology disciplines. These include flow cytometry, histopathology, molecular diagnostics and cytogenetics. Integration of these individual components into a single department dedicated to the diagnosis of haematological malignancy has many advantages and ultimately considerable patient benefit. In order for laboratories of this complexity to function effectively they will need to serve a minimum population of 500 000 and it is suggested that each laboratory should serve one or more cancer networks.
Over the last 10 years this approach has been successfully pioneered within the United Kingdom at the Haematological Malignancy Diagnostic Service (HMDS) laboratory within the Leeds Teaching Hospitals NHS trust. There is full integration of morphology, histopathology, immunophenotyping (flow cytometry and immunohistochemistry) and molecular genetics. Traditional metaphase cytogenetics still remains to be fully integrated into the service and currently remains part of clinical cytogenetics and physically separate from the remainder of service. However, requesting of tests and reporting of results including cytogenetics is fully integrated through a customized, web-based, laboratory IT system that operates within the NHS intranet.
Departmental origins
The department was originally formed in 1993 through amalgamation of the Yorkshire Regional Leukaemia Diagnosis Service and the Yorkshire Regional Cancer Organization Histopathology Laboratory. Molecular diagnostics at the time were under development as part of the leukaemia diagnostic service but became fully incorporated when the departments moved into one physical location. It was evident almost immediately that there were major advantages to having a single laboratory that dealt exclusively with diagnosis of haematological malignancy (Jack & Morgan, 1998) . Since then, significant advances have been made in rationalizing investigations and appreciating the strengths and limitations of molecular, cytogenetic, histological and flow cytometry testing as individual methods for the diagnosis of leukaemia and lymphoma. The range of diagnostic investigations has diversified considerably since the early 1990s (Table 1) and the complexity of data now generated from contemporary investigations is considerable and requires expert interpretation. The development of new technologies together with fundamental advances in understanding the biology of disease has meant that present-day leukaemia diagnosis is now vastly different from routine practise 10-15 years ago (Shaffer, Rosenwald & Staudt, 2002; Tenen, 2003) . Furthermore, the emphasis of laboratory work is now based around providing a diagnosis together with prognostic information that effectively guides therapy and patient management throughout their disease course. Monitoring response to therapy is an increasingly important part of the laboratory service.
HMDS today
The HMDS laboratory currently lies within the department of haematology, although it functions essentially as an independent unit in terms of management, finance and scientific direction. HMDS has full accreditation by Clinical Pathology Accreditation UK Ltd (CPA), which is now mandatory for all pathology laboratories in England (Department of Health, 2003) . As the majority of the work undertaken in the laboratory has direct consequences for patient management, the department in reality forms an inseparable part of both adult and paediatric clinical haematology units. The core laboratory activity is based around service work from 14 hospitals within the west and north Yorkshire regions. Work is funded on the basis of block contracts with NHS purchasing authorities that allow users unlimited use of the service. Although costs of individual patient requests are high in comparison with other routine pathology services, the costs remain relatively low in proportion to the full costs of chemotherapy or monoclonal antibody therapy for an individual patient. A further 10-20% of work is derived from supporting Medical Research Council (MRC) and other national clinical trials, specialist investigations such as paroxysmal nocturnal haemoglobinuria screening, and referrals of difficult cases from other UK hospitals. Complex Human genome project molecular investigations from other hospitals unable to perform this kind of work are also undertaken. These latter items are charged on a cost per item basis. The department not only provides diagnostic services for other hospitals within the region but also actively participates in other local haemato-oncology networks by providing expert diagnostic input and case review at their multi-disciplinary team (MDT) meetings. The volume of work in this area has expanded considerably in the last 12 months and now occupies equivalent to a whole time consultant post.
Laboratory investigations and sample processing
Since the inception of HMDS, workload in terms of requests and number of tests performed has increased year-on-year and now reaches over 10 500 patient requests per year. An individual patient request can comprise more than one specimen type and may include peripheral blood, bone marrow aspirate and trephine biopsies, and lymph node or other tissue specimens. This submission of multiple sample types is strongly encouraged by the department as it allows for a co-ordinated series of investigations to be performed focusing on specific clinical problems. Furthermore, unnecessary duplication of tests and producing potentially conflicting reports from different sample types is avoided. Not only has the number of requests per annum increased over the last decade but so has the complexity and breadth of investigations performed. In order to maintain an effective service, astute selection of appropriate tests is essential. Standard sets of investigations are requested based usually on an initial morphological screening process of either liquid (blood or bone marrow) or tissue biopsies. The decision as to which tests are appropriate for specific disorders is based on a critical examination of the evidence from published literature together with a continuous audit of in-house data. This latter approach has allowed stratification of tests into primary and secondary investigations and provided evidence for major rationalization of metaphase cytogenetic and molecular genetic testing (Owen et al., 2003) . It is clear that molecular-based methods and metaphase cytogenetics have clear roles as secondary investigations and should not be used as general screening tests for patients at presentation (Figure 1 ). The results from these investigations are uninterpretable in the absence of morphology or phenotypic data from flow cytometry or immunocytochemistry. A further advantage of using multiple modalities for investigating samples is that accurate crosschecking of results can be achieved and any potential discrepancies further investigated. This approach is particularly valuable for acute leukaemia where the pattern of antigen expression as determined by multi-colour flow cytometry frequently reflects the genotype of the disease and is predictive for the underlying molecular abnormality (Hrusak & Porwit-MacDonald, 2002) . A different approach Until this has occurred the results remain provisional. At this stage the IT system also randomly selects cases for independent audit. (e) The additional typewritten report may be produced up to a week after the first report and will contain additional information regarding prognostic markers or confirming the presence of diagnostic molecular abnormalities.
is required for follow-up samples where response to therapy and remission status is assessed. In instances where specific molecular abnormalities were present at diagnosis, e.g. t(15;17) in acute promyelocytic leukaemia or bcr/abl in chronic myeloid leukaemia, molecular or cytogenetic testing become the primary methods of investigation for assessing treatment responses and identifying high-risk patients.
When specimens or biopsies are referred to HMDS they are ÔinvestigatedÕ using standardized protocols rather than in response to individual requests for tests from referring clinicians. It is essential that investigation protocols be designed to maximize the extent of cross validation of tests rather than ordering investigations simply to ÔconfirmÕ a morphological impression. This approach allows a more systematic investigation of patients and importantly generates data that can be continually audited. Many of the standardized investigation protocols are disease specific although some of these categories are quite wide, e.g. B-lymphoproliferative disorders. These protocols can be supplemented with additional specific tests to confirm a diagnosis or provide baseline assessments for subsequent minimal residual disease studies. For example, in suspected cases of hairy cell leukaemia additional immunophenotyping will be undertaken to confirm the diagnosis. Similarly, for suspected cases of follicular lymphoma based on immunophenotype or histology, polymerase chain reaction (PCR) and fluorescent in situ hybridization (FISH)-based investigations will be undertaken to test for the t(14;18) cytogenetic abnormality. Once investigations have been completed, a patient-specific report is generated that contains information on all samples received and provides a clinically relevant conclusion or diagnosis based on standard departmental diagnostic criteria. This report may be updated later once information from diagnostic molecular genetic testing or prognostic markers is available and a second report issued with additional appropriate comments.
Diagnostic criteria
Having robust diagnostic criteria for all the major categories of haematological malignancy is essential as they not only provide a basis for consistent interpretation and reporting of results, but also provide a means of audit. Furthermore, these criteria can be directly related to the standard laboratory protocols that are used for investigating samples. Having agreed diagnostic criteria is essential for high throughput laboratories such as HMDS where up to eight individuals can be issuing patient reports. Primarily this ensures standardization in reporting terminology but additionally facilitates critical diagnosis checking of all new cases of haematological malignancy by a second reporter. Although many of the HMDS diagnostic categories comply with those published by the (World Health Organization (2001), we also have specific diagnostic categories for disorders that are not well categorized in the WHO scheme or whose existence is based on arbitrary or little published evidence. We also include more specific definitions of variant diagnosis cases and what additional cellular or genetic features are required to amend a diagnosis to atypical. It is also important to be able to rapidly incorporate new improved diagnostic or prognostic markers and also to be able to add new disease entities, particularly when these are founded on either multi-centre clinical trials or unequivocal evidence from the literature. To aid users of the service a detailed description of the diagnostic criteria are present on the departmental website [http://www.hmds.org.uk].
IT/Reporting
The nature, complexity and rapidly expanding volume of work has necessitated the development of an in-house specimen tracking system which has now been in use for over 18 months. The system, HMDS integrated laboratory information system (HILIS) has been further developed to include reporting, audit and an e-mail capability for critical diagnoses, i.e. all newly presenting cases of leukaemia and lymphoma. The system was initially developed to standardize test-requesting profiles for individual disease entities and also to keep track of outstanding investigations particularly those that because of their complexity and expense need to be performed in batches rather than as individual tests. These investigations, typically molecular and FISH-based tests usually provide prognostic information or definitive diagnostic information. The HILIS system also allows individual service users from other hospitals to monitor progress of patient requests and access to final diagnosis summaries. By having a direct e-mail facility built into the system, rapid despatch of critical diagnostic summary reports can be achieved that allows timely inclusion of new patients into local multi-disciplinary team (MDT) meetings. This process of increasing the number of reports sent by electronic means is in line with recommendations from the Department of Health (2002) .
In order to comply with CPA standards we have a departmental web site (http://www.hmds.org.uk) that not only contains general information about the department but also has specific information for service users. This approach is much more realistic than having a Ôuser handbookÕ as many features are subject to continual updating. This approach is more efficient and cost effective than paper copies and provides a general source of information for potential and current users.
Staffing and training
In a laboratory where the range of complex diagnostic techniques is considerable there is a requirement for both specialist technical expertise and interpretive experience. This is reflected in a broad staffing mix within the department comprising biomedical scientists, clinical scientists, haematopathologists, clinical haematologists and support staff. There will, in the near future, be a requirement for a specialist haematological cytogeneticist to be based within the department. Within HMDS there are excellent opportunities for training medical, scientific and technical staff, and many of the current staff have completed higher research degrees as part of their training and personal development programmes. The majority of the technical staff have core competencies in molecular biology, flow cytometry, FISH and histology. This wide range of technical skills is essential for both personal development and for maintaining a flexible work force to cover busy periods, holidays and the on-call service. Similarly, it is important that senior staff involved in generating patient reports are able to interpret data from all the diagnostic techniques and are aware of the limitations of these methods. Much of this is achieved through formal teaching and staff rotation through the individual specialist technical sections of histology, flow cytometry and molecular/FISH.
Following implementation of the NICE guidelines the demand for centralized haematopathology services as a speciality will undoubtedly increase. With this predicted expansion there will be a demand for formally trained individuals from all professional staffing groups in this area. Discussions are at an early stage as to how formal multidisciplinary training schemes can be developed. As clinical scientists undertake the majority of scientific developmental work within the department a sustainable supply of suitably trained clinical scientists is required to fulfil this key role. The department is developing an in-house training programme for grade A clinical scientists and intends to seek official recognition for this from the British Society for Haematology in order to become an accredited training centre.
Research and development
An essential component of the department is a carefully structured research and development programme. This is focused in three main areas clinical, epidemiological and laboratory studies, all of which are essential for service development and maintaining the departmental profile. The clinical and epidemiological research areas reflect the individual interests of senior members of the department. The laboratory research, which is predominantly translational in nature, is aimed at future service requirements. The department is closely linked to the academic department of haematology and oncology. This relationship is again seen as essential in terms of access to expertise in molecular biology technologies which may rapidly become important diagnostic tools, e.g. gene sequencing, microarray technology.
As stated previously, the majority of the work undertaken within the department is highly patient specific and closely integrated with the regional clinical haematology units. Full integration of both clinical and developmental work is a feature of the department and has led to the development of novel methods of monitoring disease levels during and after treatment [Rawstron et al., 2001] . The implications for this kind of development are significant, particularly for the more common diseases such as chronic lymphocytic leukaemia and myeloma. Initially, they can provide very accurate predictions about disease course and future therapeutic requirements. Finally, they attract additional external research funding for the department.
What lessons have been learnt?
The implications for health authorities or pathology networks wanting to establish a similar integrated laboratory service for the diagnosis of haematological malignancies based on the HMDS model are considerable. Funding issues will be a concern both in terms of employing expert staff and purchasing expensive sophisticated equipment. Long-term issues include being able to respond to rapid developments in both diagnostic technologies, demands for new tests and more frequent tests based on more successful therapies. Many of the developmental issues could be addressed nationally through a network of HMDS-type laboratories and sharing of resources. From our own experience, it is clear that once this type of service is established, workload increases substantially. This again has implications for additional funding and staffing requirements to meet the increased demand and mechanisms need to be in place to allow this to be addressed in a timely manner. One of the most critical areas for an effective service is the IT system. This should ideally encompass as many possible areas that are essential for a contemporary clinical laboratory service. These should include standardized test requesting profiles, a means of continuous audit, critical diagnosis checking and email capabilities for urgent results.
Summary and future directions
The NICE guidelines recommend that patients with haematological malignancy are to be managed by multidisciplinary haemato-oncology teams that will serve populations of greater than 500 000. The requirement for the results of laboratory investigations and diagnosis of all cases of haematological malignancy to be reviewed by experts and specialist haematopathologists essentially points towards significant growth in the area as a distinct speciality. The recognition by NICE that Ôthis approach is best achieved by locating all specialist diagnostic services in a single, specialist laboratoryÕ reflects the importance of integration of results of an increasingly diverse range of investigations in order to achieve a correct diagnosis. The benefits of having this type of integrated service are considerable. It ensures that specialist laboratory services become an integral part of cancer networks and part of the overall national strategy for improving outcomes in patients with haematological malignancies.
